Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 23UNKNOWN 1OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Radiotherapy, Intensity-Modulated 3Radiotherapy 2Epirubicin 2Cytarabine 2pirarubicin 1durvalumab 1aclacinomycins 1Temozolomide 1Sorafenib 1Radiotherapy, Adjuvant 1Radiation Dose Hypofractionation 1Povidone-Iodine 1Pleurodesis 1Paclitaxel 1Nutrition Assessment 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Methylene Blue 1Indocyanine Green 1Equipment and Supplies 1Drug Therapy 1Doxorubicin 1Docetaxel 1Daunorubicin 1Cyclophosphamide 1Cabergoline 1CAG protocol 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × UNKNOWN × Sorafenib × Clear all
NCT02537158 2016-03-15

Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection

ChineseAMS

Phase NA Unknown
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡